Search Results - "Rocha Lima, C. M. S."

EUS-FNA with rescue FISH for the diagnosis of pancreatic carcinoma in patients with inconclusive on-site cytopathology by Akunyili, I. I., Rocha Lima, C. M. S., Macintyre, J., Solis, N., Merchan, J. R., Sleeman, D., Levi, J. U., Ribeiro, A.

“…Abstract only…”
Get full text

Irinotecan Plus Gemcitabine Induces Both Radiographic and CA 19-9 Tumor Marker Responses in Patients With Previously Untreated Advanced Pancreatic Cancer by Rocha Lima, C. M. S.

Get full text

Combination study of navitoclax with gemcitabine (G) in patients (pts) with solid tumors by Cleary, J. M., Rocha Lima, C. M. S., Hurwitz, H., Montero, A. J., Shapiro, G., Franklin, C., Yang, J., Graham, A. M., Busman, T., Mabry, M., Holen, K. D., Krivoshik, A., Humerickhouse, R., Uronis, H.

“…Abstract only…”
Get full text

Phase I trial of weekly and every 3 weeks ixabepilone (Ix) and sunitinib (S) in advanced solid tumors (STs) by Kittaneh, M., Montero, A. J., Kovacs, K., Guardiola Amado, V. D., Flores, A. M., Ferrell, A., Vulfovich, M., Pegram, M. D., Benedetto, P. W., Rocha Lima, C. M. S., Merchan, J. R.

“…Abstract only…”
Get full text

Global, multicenter, open-label, randomized phase II trial comparing gemcitabine (G) with. G plus AGS-1C4D4 (A) in patients (pts) with metastatic pancreatic cancer (mPC) by Wolpin, B. M., O'Reilly, E. M., Ko, Y., Blaszkowsky, L. S., Rarick, M. U., Rocha Lima, C. M. S., Ritch, P. S., Chan, E., Spratlin, J. L., Macarulla, T., McWhirter, E., Pezet, D., Lichinitser, M., Roman, L. D., Hartford, A., Jackson, L., Vincent, M., Reyno, L. M., Hidalgo, M.

“…Abstract only…”
Get full text

Phase II trial of paclitaxel-topotecan-etoposide (PTE) followed by consolidation chemoradiotherapy for limited stage small cell lung cancer (LS-SCLC): CALGB 30002 by Miller, A. A., Bogart, J. A., Watson, D. M., Wang, X. F., Rocha Lima, C. M. S., Vokes, E. E., Green, M. R.

“…Abstract only…”
Get full text

Bortezomib ± irinotecan in relapsed/refractory colorectal cancer (CRC): Interim analysis results from phase (ph) 2b study by Dragovich, T., Lenz, H. J., Rocha Lima, C. M. S., Kozuch, P., Hochster, H., O'Neil, B., Atiq, O., Pipas, J. M., Kashala, O., Schenkein, D. P.

“…Abstract only…”
Get full text

Bortezomib ± irinotecan in relapsed/refractory colorectal cancer (CRC): Interim analysis results from phase (ph) 2b study by Dragovich, T., Lenz, H. J., Rocha Lima, C. M. S., Kozuch, P., Hochster, H., O'Neil, B., Atiq, O., Pipas, J. M., Kashala, O., Schenkein, D. P.

“…Abstract only…”
Get full text

Synergistic effect of gemcitabine and irinotecan (CPT-11) on breast and small cell lung cancer cell lines by Bahadori, H R, Rocha Lima, C M, Green, M R, Safa, A R

“…Gemcitabine (2'-2'-difluorodeoxycytidine, dFdC), an analog of deoxycytidine, is an antineoplastic agent with clinical activity against several types of cancer…”
Get more information

Single-agent gemcitabine and gemcitabine/irinotecan combination (irimogem) in non-small cell lung cancer by Rocha Lima, C M, Eckardt, J R, Leong, S S, Sherman, C A, Perkel, J A, Putman, T, Safa, A R, Bahadori, H R, Green, M R

“…Gemcitabine is a fluoridated pyrimidine related to cytosine arabinoside that has significant activity in solid tumor models. Irinotecan is a camptothecin…”
Get more information